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1. Introduction
Autophagy an evolutionarily conserved process, is activated in response to nutrient depriva‐
tion, as well as to endogenous and exogenous stresses. It is currently known that the basic
mechanism of autophagy has been well conserved during evolution since diverse organisms,
including yeast, flies, and mammals, all carry a similar set of autophagy-related genes (ATGs),
although there are some significant differences between yeast and higher eukaryotes. As a
result, autophagy is a highly regulated process known to contribute to cellular cleaning
through the removal of intracellular components in lysosomes showing therefore an important
role in cellular quality control. Autophagy ensures that proteins damaged or incorrectly
synthesized are removed from the cells by degradation, preventing thus the devastating
cellular consequences associated with accumulation of malfunctioning proteins inside cells.
Moreover autophagy works as a recycling system where it mediates the breakdown of proteins
that are no longer needed into essential components (aminoacids, free fatty acids, sugars),
which can then be used in the synthesis of new proteins. This has extreme importance in
conditions of nutritional stress or starvation. At optimal physiological conditions in the
absence of stressors, basal level of autophagy assures maintenance of cell homeostasis through
regular turnover of proteins, lipids, and organelles. Therefore autophagy acts a cautious
controller of cellular homeostasis. In addition, it also has an important role in cellular defence
as in compromised situations it contributes to the proteolytic breakdown of components of
invading pathogens and other types of biological cell aggressors. Autophagy may also
modulate synaptic plasticity, which involves structural remodelling of nerve terminals and
the trafficking and degradation of receptors and other synaptic proteins [1]. Finally, autophagy
is also a key player in cellular adaptation since is able of changing very rapidly the rate of a
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particular protein’s degradation allowing fast modulation of the proteome in response to
stress. The lysosomal system and specifically the autophagic pathway is the principal mech‐
anism for degradating longer-lived proteins and is the only system in cells capable of degrad‐
ing organelles and protein aggregates/inclusions. Similar to what happens with the
proteasome system, protein aggregates and certain organelles have been shown to be tagged
with ubiquitination for selective removal by autophagy [2]. An adaptor molecule with an
ubiquitin-binding domain engages the ubiquitinated structure and couples it to the pre-
autophagosomal isolation membrane for subsequent sequestration. The exact types of
ubiquitin motifs recognized by the proteasome and autophagy may differ and the degree to
which ubiquitination drives autophagic protein turn-over relative to that by proteasomes is
still unclear.
There are three basic forms of autophagy, namely, macroautophagy, microautophagy and
chaperone-mediated autophagy (CMA), which primarily differ in the way in which cytosolic
components are delivered to lysosomes [3]. Moreover, the different types of autophagy share
a common endpoint, the lysosome, but differ in the substrates targeted, their regulation, and
the conditions in which each of them is preferentially activated.
In macroautophagy and microautophagy there is the sequestration of cytoplasmic components
into vesicular compartments. In the case of macroautophagy, vesicles are form de novo from a
limiting membrane of non-lysosomal origin that closes and forms a double membrane
organelle called autophagosome [4]. Because the autophagosome lacks any enzymes, the
trapped contents are not degraded until the autophagosome fuses with a lysosome, which
provides all the hydrolases required for degradation of cargo. Autophagosomes are then
transported along microtubules to the perinuclear region of the cell (where lysosomes are
clustered) to enhance the probability of autophagosome-lysosome fusion to form autophago‐
lysosomes. Lysosomes are single membrane organelles dedicated to degradation of both
intracellular and extracellular components. Lysosomal membranes possess vacuolar H+
ATPases which are proton pumps that acidificate the autophagolysosome contents. This
acidification is essential for the activation of lysosomal enzymes (including proteases, lipases,
glycosidases, and nucleases), which are responsible for proteolysis of the components in the
autophagolysosome and confer this organelle its high degradative capacity [5]. Although
autophagy was initially considered to be a nonselective process, cargo-specific autophagy (the
selective degradation of certain aggregated proteins and organelles) is now recognized to exist
[6]. Numerous different types of cargo-specific autophagic processes have been described, like
for instance mitophagy where damaged mitochondria are sequestered and degraded [7].
Macroautophagy occurs constitutively in cells and is markedly induced under stress condi‐
tions, such as starvation and has two major purposes: as a source to generate essential
macromolecules and energy in conditions of nutritional scarcity, or as a mechanism for the
removal of altered intracellular components [8].
In the case of microautophagy the engulfment of cargo occurs through invagination of the
lysosomal membrane itself, to form vesicles that invaginate towards the lysosomal lumen [9].
Cytosolic regions are sequestered directly by the lysosome through invaginations or tubula‐
tions that “pinch off” from the membrane into the lysosomal lumen where they are rapidly
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degraded. Microautophagy participates in the continuous, slow “basal” turnover of cellular
components in normal cellular conditions [10]. Furthermore microautophagy has been shown
to be responsible for the selective removal of organelles when they are no longer needed [11].
The absence of mammalian homologs for the microautophagy yeast genes has made it difficult
in gaining a better understanding of the pathophysiology of this process.
The third type of mammalian autophagy CMA distinguishes from the others because of its
distinctive feature of selectivity. Unlike the other forms of autophagy, in which portions of the
cytoplasm are typically engulfed, proteins degraded by CMA are identified and transported
one-by-one by a cytosolic chaperone that delivers them to the surface of the lysosomes. First
there is individual recognition of single proteins in the citosol, then the substrate proteins
unfold and cross the lysosomal membrane. Only soluble proteins containing in their aminoacid
sequence a pentapeptide motif related to KFERQ, are recognized by heat shock cognate protein
of 70 kDa, hsc70, which mediates their delivery to the lysosomes for direct translocation across
the lysosomal membrane [3, 12]. These pentapeptide motifs are recognized specifically by the
cytosolic protein hsc70, the constitutively expressed member of the hsp70 family of cytosolic
chaperones. hsc70 not only targets the CMA substract to the lysosomal membrane where it
can interact with the CMA receptor but also facilitates substrate folding [13]. A second
chaperone that also localizes on both sides of the lysosomal membrane is the heat shock protein
of 90 kDa, hsp90. hsp90 is proposed to participate in substrate protein unfolding [14], and
contributes to the stabilization of essential components of the translocation complex as they
organize into a multimeric structure [15]. Additionally, the co-chaperone carboxyl terminus
of Hsp70-interacting protein (CHIP) has been shown to mediate lysosomal degradation of
proteins such as alpha-synuclein, a known CMA substrate [16], however, it is still undergoing
investigation whether CHIP-mediated degradation occurs via CMA or via other forms of
autophagy. The lysosome-associated membrane protein type 2A (LAMP-2A) acts as a receptor
for substrates of this pathway [17]. This protein is one of the three splice variants encoded by
the lamp2 gene that share identical lumenal regions and different transmembrane and
cytosolic tails [18]. Once the cytosolic proteins destined for CMA degradation bind to the
cytosolic tail of the single-span membrane protein LAMP-2A, they promote its assembly into
a high molecular weight complex of about 700 kDa at the lysosomal membrane required for
translocation of the CMA substrates into the lysosomal lumen [15]. Multimerization is a
required step for substrate translocation. However, the translocation complex is not stable at
the lysosomal membrane and, once the substrate reaches the lysosomal lumen, LAMP-2A
dissociates into monomers. hsc70 mediates the disassembly generating monomeric forms of
LAMP-2A that are required for substrate binding in order to sustain cycles of binding and
uptake. Other proteins have been shown to modulate the stability of the CMA translocation
complex, such as, glial fibrillary acidic protein (GFAP) and elongation factor 1 a (EF1a). One
of the crucial functions of CMA is protein quality control via the selective degradation of
damaged or altered proteins. Moreover proteins associated with several neurodegeneratives
disorders have KFERQ-like sequences such as, alpha-synuclein, parkin, UCHL1 and Pink1,
amyloid precursor protein (APP) and tau and huntingtin. These proteins can be degraded by
CMA only when they are in soluble forms; once the insoluble inclusions are formed, they can
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only be degraded via other proteolytic pathways [19]. CMA is constitutively active in many
cell types and similar to macroautophagy, CMA is maximally activated under stress conditions
like nutritional stress or starvation and cellular stresses leading to protein damage [3]. Indeed,
upon stressors that cause protein damage, such as oxidative stress, CMA is upregulated [20].
During starvation, macroautophagy is first activated, and if starvation persists, cells activate
CMA, which selectively targets non-essential proteins for degradation to obtain the aminoa‐
cids required for the synthesis of essential proteins showing that macroautophagy and CMA
act in a synchronized manner [21]. There are two lysosomal components that limit CMA
activity: LAMP-2A and lys-hsc70. It is known that changes in the number of LAMP-2A
molecules, as well as, in the membrane content of LAMP-2A, rapidly upregulate or downre‐
gulate CMA activity [17]. Levels of lys-hsc70 increase gradually with the increase in CMA
activity, although the mechanisms modulating this increase are still poorly understood [14].
Furthermore, the activity of this autophagic pathway is also directly modulated by changes in
other autophagic and proteolytic systems inside the cell. For examples, cells in culture respond
to CMA blockage by upregulating macroautophagy [21]. Likewise, blockage of macroautoph‐
agy results in constitutive activation of CMA [22].
The identification of ATGs in yeast was a major breakthrough in the study of autophagy [23].
Until now more than 35 ATG genes have been found in yeast and many of them have orthologs
in mammals to control the dynamic processes and different stages of autophagy. Indeed,
autophagic activities are mediated by a complex molecular machinery including more than 35
ATG-related proteins and 50 lysosomal hydrolases. This dynamic macroautophagic process
includes initiation, nucleation, elongation, maturation and degradation. Initiation involves
formation of the phagophore, a cup-shaped membrane structure in the cytoplasm. Nucleation
involves the recruitment and assembly of several proteins including Beclin-1 and Vps34,
among others [24]. Vps34 has a phosphoinositide 3-kinase (PI3K) activity and produces
phosphatidylinositol 3-phosphate, which recruits molecular components involved in subse‐
quent vesicle elongation. Subsequently elongation is a critical step in forming the complete
autophagosomes and is controlled by two ubiquitin-like conjugation systems. The first
involves the Atg7 E1-like enzyme that mediates the covalent linkage of Atg12 to Atg5 followed
by formation of a complex of Atg12-Atg5 with Atg16L, which dimerizes and associates with
the phagophore membrane. In the second one LC3 has to be cleaved by Atg4 to generate the
cytosolic LC3 (that arises from microtubular-associated protein-light chain) that can subse‐
quently be conjugated to a phosphatidylethanolamine tag by Atg7 and the E2-like enzyme
Atg3. The resulting lipidated form of LC3, LC3-II, is attached to both sides of the autophago‐
some membrane. LC3-II is clearly necessary for autophagosome formation and is commonly
used as a marker for autophagy. Finally, maturation and degradation steps, involves fusion
with endosomes-lysosomes to form autophagic vacuoles (AVs) and requires a number of
lysosomal proteins necessary for the degradation of the lumenal contents [25]. The transmem‐
brane Atg9 protein also contributes to autophagic vesicle nucleation and elongation, possibly
by mediating the transport of lipid molecules. At this stage, LC3 on the outer autophagosome
membrane is removed by Atg4 for reuse, while inner membrane LC3-II is digested along with
the cargo. The rate-limiting step in the autophagic process is autophagosome formation.
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Autophagy can be regulated by mTOR-dependent signaling pathways and mTOR-independ‐
ent signaling pathways. The serine–threonine kinase mTOR is a master negative regulator of
autophagy that acts by blocking the activity of the ULK1/Atg1 complex [26]. mTOR is inhibited
when nutrients are scarce, when growth factor signaling is reduced, and under ATP depletion.
When mTOR is inhibited and the repressive effect of mTOR on autophagosome formation
disappears an increase in autophagosome biogenesis occurs [27]. In pathways that act
independently of mTOR, when in nutrient-rich conditions, Beclin-1 is bound to the antiapop‐
totic protein Bcl-2. Under nutrient starvation, the stress-activated enzyme Jun N-terminal
kinase 1 (JNK1) phosphorylates Bcl-2, which induces its dissociation from Beclin-1 [28]. Beclin
can then interact with other members of the autophagic machinery and stimulate the induction
of autophagy [29-30]. One of the mTOR-independent pathways can be mediated by the IP3
pathway and the Ca2+–calpain–G-stimulatory protein alpha pathway [31]. Generation of IP3
induces the release of Ca2+ from stores in the endoplasmic reticulum and high levels of cytosolic
Ca2+ inhibit autophagy by activating calpains. After cleavage by calpains, the Ca2+–calpain–G-
stimulatory protein alpha pathway becomes activated which, in turn, causes the production
of more inhibitory cAMP [31]. On the other hand, decreased levels of IP3 signaling leads to
reduced Ca2+ release from the endoplasmic reticulum and lower rates of mitochondrial Ca2+
uptake, causing a reduction in mitochondrial activity and ATP depletion, which results in 5'-
AMP-activated protein kinase (AMPK) activation [32]. Activated AMPK directly phosphory‐
lates ULK1, indirectly inactivating mTOR complex which leads to the induction of autophagy.
2. Autophagic failure at cellular level
Two of the main aggravating factors contributing to failure of autophagic pathways are
believed to be oxidative stress and aging. Aging can lead to reductions in autophagosome
formation and autophagosome-lysosome fusion [33]. Moreover leads to lysosomal alterations
such as increased lysosome volume, decreased lysosomal stability, altered activity of hydro‐
lases and intralysosomal accumulation of indigestible material such as lipofuscin [34]. These
alterations are consistent with a decrease in autophagy, more specifically macroautophagy.
Consequently, there is a reduction in the turnover of intracellular components as well as a
reduction in the ability of cells to adapt to changes in the extracellular environment [35].
Ultimately this contributes to the intracellular accumulation of misfolded proteins in aged
organisms [36]. Moreover, also a decline in CMA activity has been described in almost all cell
types and tissues. This decrease is primarily due to a reduction in the levels of LAMP-2A at
the lysosomal membrane [37]. In addition, the stability of LAMP-2A at the lysosomal mem‐
brane is markedly reduced with age, resulting in a decrease in the net content of this protein
in lysosomes [38].
On the other hand, oxidative stress overloads the macroautophagic system, and oxidized
proteins and damaged organelles engulfed by autophagosomes can become a source of ROS
inside either autophagosomes or lysosomes. Subsequently ROS can react and damage
lysosomal hydrolases and/or other components required for the lysosome/autophagosome
fusion, resulting in the accumulation of undegraded products inside these cellular compart‐
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ments, such as lipofuscin. Defects in basal autophagy could lead to altered neuronal homeo‐
stasis and degeneration through impaired utilization of nutrients or an imbalance of vesicular
biogenesis and turnover. Alternatively, neuronal dysfunction might be a more direct result of
failed protein degradation with resultant accumulation of ubiquitinated protein aggregates.
2.1. Lipofuscin accumulation
The most abundant pigment in the human brain is lipofuscin, a protein- and lipid-based
pigment with broad distribution [39]. Lipofuscin is commonly considered to be a ubiquitous
pigment within the brain, being recognized as a hallmark of aging [40]. Lipofuscin is a
chemically and morphologically polymorphous and pigmented waste material that is formed
exclusively in lysosomes where it can accumulate as well as in other lysosome-related vesicles
due to incomplete digestion of engulfed components and subsequent intra-lysosomal oxida‐
tion [41]. Ivy and co-workers suggested that lipofuscin accumulation might result from age-
related decrease in the activity of lysosomal enzymes, especially cysteine proteases, such as
cathepsins B, H, and L [42]. However where some studies showed a decrease in lysosomal
cysteine protease activity others did not because lipofuscin starts to accumulate immediately
after birth and continues to do so more or less linearly through the life span [41]. Lipofuscin
formation appears to depend on the rate of oxidative damage to proteins, the functionality of
mitochondrial repair systems, the proteasomal system, and the functionality and effectiveness
of the lysosomes. Major factors that contribute and enhance lipofuscin formation are increased
autophagic activity, increased oxidative stress or decreased antioxidant defences, and high
concentrations within the lysosomes of redox-active iron [43].
The cell recycles many of useful substrates by autophagic degradation to simple molecules,
such as aminoacids, fatty acids and simple sugars, which may be reused after relocalization to
the cytosol. Many of these macromolecules that are autophagocytosed contain iron, which is
released from a variety of metalloproteins during their intralysosomal degradation [43].
Moreover ROS (mainly H2O2, which is produced in mitochondria by dismutation of O2•-) easily
diffuse into lysosomes and by interacting with iron results in Fenton-type reactions which
leads to excessive production of ROS and peroxidation of lysosomal protein content. Moreover
the newly generated ROS are then able to interact with the proteins and lipids within the
lysosome and form a complex array of Schiff bases and cross-linking of surrounding macro‐
molecules culminating in lipofuscin formation [44]. This is supported by data that demon‐
strates that oxidative stress, high iron or decreased antioxidant systems stimulate lipofuscin
formation whereas antioxidants and iron chelators attenuate lipofuscin formation [39].
Furthermore, oxidatively damaged mitochondria may contain some already peroxidized,
undegradable macromolecules. In addition, such ineffective mitochondria are not only
ferruginous but also may generate larger amounts of O2•- than do functional mitochondria.
Inside the lysosome, such production of O2•- may continue for a while, as well as, iron-catalyzed
oxidative modification of mitochondrial components. Moreover ATP synthase subunit c, a
mitochondrial protein is a predominant component of lipofuscin from aged neurons [45].
Indeed, autophagocytosed mitochondria seem to be a major source for both macromolecular
components of lipofuscin and the low mass iron that catalyzes the peroxidative reactions
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resulting in its formation. Therefore the primary constituents of lipofuscin are oxidatively
modified protein residues, which are bridged into polymer complexes by acids, and lipid
residues such as reactive aldehydes originating from the breakdown of triglycerides, free fatty
acids, cholesterol and phospholipids, while carbohydrates form only a minor structural
component [33]. Proteins within lipofuscin are linked by intramolecular and intermolecular
cross-links; many of these cross-links are caused by nonproteineous compounds including
oxidation products of other cellular components, such as 4-hydoxy-2-nonenal. Overall, the
composition of lipofuscin is variable and dependent upon cell type, but in neurons, lipofuscin
appears to be derived primarily from autophagocytosed mitochondria [46].
Hence, lipofuscin accumulation in post-mitotic tissues is both a hallmark of normal senescence
and symptomatic of numerous age-related diseases including Alzheimer’s disease (AD) and
age-related macular degeneration. In addition, lysosomal storage diseases (neuronal ceroid
lipofuscinosis, or Batten’s disease) are also associated with the accumulation of lysosomal
pigment displaying properties similar to that typical of lipofuscin. Lipofuscin complex is
undegradable as the result of the excessive oxidation and cross-linking that occurs during its
formation leading to the inability of the lysosome to degrade all incorporated materials.
Lipofuscin inherently causes toxic effects, in part because of its ability to bind metals, such as
iron, copper, zinc, manganese, and calcium, in a concentration up to 2% [47]. Being rich in
heavy metals such as iron lipofuscin may jeopardize lysosomal stability under severe oxidative
stress, causing enhanced lysosomal rupture and consequent apoptosis/necrosis. The only
known mechanism allowing cells to get rid of lipofuscin is mitotic activity, which results in
the dilution of the pigment. When lysosomes accumulate lipofuscin, lysosomal enzymes
increasingly go to lipofuscin loaded lysosomes in an attempt to degrade the non-degradable
material. Since the capacity to produce lysosomal enzymes for autophagy is not unlimited, the
lack of lysosomal enzymes for autophagy leads to reduced ability to recycle other cellular
organelles, such as mitochondria. Hence lipofuscin acts as a sink for newly produced lysosomal
enzymes. If damaged mitochondria are not eliminated this subsequently results in a lower rate
of ATP production and increased ROS production. Moreover, the release of the abundant iron
from the aged intralysosomal compartment by free-radical-mediated membrane damage will
also stimulate free radical production via Fenton chemistry, possibly leading to apoptotic cell
death [46]. On the other hand, large numbers of lipofuscin-containing lysosomes, which also
contain active hydrolases, may promote cellular damage if lysosomal membranes are desta‐
bilized by pathogenic factors (including oxidative stress), resulting in leak of hydrolytic
enzymes into the cytosol. Because lipofuscin is separated from the rest of the cytoplasm by the
lysosomal membrane, it cannot react directly with extralysosomal constituents. However,
within lysosomes loaded lipofuscin iron may promote ROS production, sensitizing cells to
oxidative injury through lysosomal destabilization. So, lipofuscin a yellowish-brown, au‐
tofluorescent, nondegradable polymeric substance that cells cannot get rid of it [48], reduce
the lysosomal degradative capacity [34]. Interestingly, the rate of lipofuscin formation is
inversely related to age and lysosomes containing lipofuscin have a reduced ability to fuse
with autophagic structures [43].
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Moreover, lipofuscin is able to decrease not only lysosomal degradation but also proteosomal
degradation, perhaps as a result of binding proteasomal complexes in unsuccessful attempts
of degradation [49]. Therefore, lipofuscin directly decreases cellular proteolysis by inhibition
of the proteasomal turnover, resulting in reduced proteasomal activity [50]. Another reason
for lipofuscin toxicity is the gradual filling of the cytoplasmic space over time, [51] resulting
at first in decreased cellular functional capability, later in apoptotic cell death. In addition, also
intracellular trafficking as well as cytoskeletal integrity may be compromised by the presence
of large intracellular aggregates.
2.2. Defective autophagy
Defects in autophagy have been described to occur at very different levels within the cell and
at very different diseases. Therefore understanding how autophagy step or steps are altered
in specific disorders is a priority. There are several examples of defects that can arise in
autophagy.
For example, initiation of autophagy may be compromised because of altered signaling
through the insulin or mTOR pathways, which is tightly bound to activation of autophagy.
Since autophagy can be cargo-specific which implicate cargo adaptors molecules that enable
autophagosomes to identify specific substrates, alterations in the organelle-specific markers
for degradation or in the autophagic machinery can impair autophagic turnover. For instance,
if autophagosomes not recognize damaged mitochondria, defects in mitophagy occur which
contributes to disease pathology, since removal of damaged mitochondria is impaired leading
to high levels of ROS. Cells are then more susceptible to proapoptotic insults. Defects in cargo
recognition occurs for instance in Huntington’s disease (HD). HD is caused by gain-of-function
mutations that confer neurotoxic effects on the ubiquitously expressed protein huntingtin [52].
This gain-of-function impairs the ability of autophagosomes to recognize certain cargoes,
while mutant huntingtin is efficiently incorporated into autophagosomes, it may reduce
autophagic sequestration of other cargoes [53].
In other conditions, autophagosomes form correctly and sequester relevant cargo but they fail
to be cleared from the cytosol. Problems with clearance could result from alterations at very
different levels. For example, problems with vesicular trafficking could indirectly interfere
with the mobilization of autophagosomes toward the lysosomal compartment [54]. The
cytoskeleton is extremely important in the trafficking of organelles and in fact has the role to
maintain the spatial organisation for autophagy by conducting the trafficking of organelles
involved in different interactions during autophagy. Therefore, autophagy is microtubule-
dependent [55]. When microtubules are disrupted by colchicine, autophagosome–lysosomal
fusion is also disrupted leading to an increase in the number of autophagic vacuoles (AVs) [56].
Pathogenic proteins can also interfere with the fusion step, which, although still not completely
elucidated at the molecular level, is known to depend on different SNARE proteins, the actin
cytoskeleton and the histone deacetylase 6 (HDAC6) [57]. Furthermore, if organelle traffic
through the axon is “jammed” we will have organelle transport problems [58].
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It is also possible that problems in maturation of autophagosomes and their fusion with
lysosomes also occur. The maturation of autophagosomes and their fusion with lysosomes is
dependent on the motor protein dynein, which mediates autophagosome movement along the
cytoskeleton towards the microtubule-organizing center where the lysosomes are clustered.
Loss of dynein function also results in the accumulation of autophagosomes and reduction of
the clearance of intracytoplasmatic aggregation-prone proteins [54].
Furthermore, lysosomal defects also have a negative impact on clearance of autophagosomes.
Autophagosomes can form properly and sequester the usual cargo but they are not eliminated
through the lysosomal system. The reasons for lysosomal failure could be multiple. For
instance in most lysosomal storage disorders (LSDs) the accumulation of undegraded products
inside lysosomes limits their degradative capacity [59]. Undigestible material in lysosomes
could build up or otherwise inhibit hydrolases, and could also dilute or divert the delivery of
lysosomal hydrolases decreasing their efficiency. Interestingly, accumulation of β-amyloid
(Aβ) 1-42, which has a high propensity to aggregate and therefore is less efficiently degraded,
causes leakage of lysosomal enzymes into the cytosol [60-61].
Moreover the build up of AVs filled with undigestible material could inhibit secretory
pathways interfering with nutrient uptake and response to growth factors or recovery from
stress. Additionally, it could also inhibit organelle fusion or block the supply of aminoacids
from autophagic protein breakdown, inducing cell starvation [62]. Additionally, conditions
that alter lysosomal membrane stability, decreases lysosomal biogenesis or changes lysosomal
pH inhibiting lysosomal proteolysis (because of the acidic pH requirements of their degrada‐
tive enzymes) could also alter autophagosome clearance. Lysosomal hydrolases inhibition by
defective acidification of the lysosomal lumen can be due to the inability to target to lysosomes
one of the subunits of the proton pump that usually acidifies this compartment, or by direct
inhibition of cathepsins that leads to reduced rates of autophagy. Changes in the lysosomal
pH could be due to enhanced activity of the V-ATPase. The V-ATPase is a holoenzyme
consisting of a membrane bound Vo and cytosolic V1 components, and both V1 and Vo are
composed of multiple subunits. The Vo subunit a1 is required for acidification of degradative
competent lysosomes [63]. Preservation of low pH is important for cargo release, lysosomal
hydrolase and vesicle maturation, autophagy and neurotransmitter loading into synaptic
vesicle [64].
Accelerated endocytosis also increases protein and lipid accumulation in endosomes and
slows lysosomal degradation of endocytic cargoes [65], leading to lysosomal instability.
The process from protein sorting to endosomal-lysosomal fusion is maintained by the sequen‐
tial interaction of four complexes termed the endosomal sorting complexes required for
transport (ESCRT complexes). The four ESCRT complexes, numbered 0–III, are required for
the degradation of aggregate-prone proteins by autophagy [66]. Mutations or depletions
affecting ESCRT related genes results in deficient maturation of autophagosomes or in their
inability to fuse with lysosomes and endosomes. This leads to autophagosomes accumulation
without degradation of their cargo, as well as, ubiquitin-positive aggregates accumulation
leading to neurodegeneration in many cases [67]. As proteasome is thought to be turned over
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by autophagy [68], blockade of proteasome turnover could disrupt additional degradative
pathways.
More specifically alterations of CMA can also occur. Different pathogenic proteins have been
shown to directly interfere with CMA activity [69]. For instance, mutant forms of alpha-
synuclein fail to translocate to the lysosomal lumen whereas the wild-type protein binds to the
lysosomal receptor and rapidly reaches the lumen for degradation. Consequently, mutant
forms of alpha-synuclein block access of other cytosolic proteins to lysosomes via CMA by
abnormally bind to the lysosomal receptor. Moreover, the accumulation at the surface of
lysosomes of oligomeric forms of pathogenic proteins targeted via CMA destabilizes the
lysosomal membrane and results in leakage of lysosomal enzymes into the cytosol, which often
triggers cellular death.
2.2.1. Consequences of defective autophagy
Healthy cells harbour a high autophagic clearance capacity preventing the “traffic jams” of
endosomes, autophagosomes, as well as, aggregated proteins and damaged organelles. Only
unfolded monomer proteins can undergo degradation through any of these two systems:
autophagy, specifically CMA and ubiquitin-proteasome system (UPS). Consequently, once
organized in oligomers, protofibrils, and fibrils, proteins can only be removed by in-bulk
degradation, such as via microautophagy or macroautophagy. Thus, oligomers and fibrils of
particular proteins can block the proteolytic activity of the UPS and of CMA. These alterations
in intracellular proteins can be due to exposure to intracellular or extracellular stressors, such
as oxidative stress, endoplasmic reticulum stress, ultraviolet radiation and other toxic insults.
In addition, genetic mutations can generate proteins that cannot fold properly or are prone to
aggregation. This can lead to the generation of misfolded proteins or modified soluble proteins
resulting from protein cross-linking and oligomerization. The most toxic forms of altered
proteins are complex organized structures, such as fibrils or oligomers, although the mecha‐
nism by which they exert their cellular toxicity is still controversial. In the absence of a properly
functioning quality control system, and as a last attempt to prevent toxicity, cells favor
formation of protein aggregates rather than fibrils and oligomeric complexes. The maturation
of misfolded or unfolded protein into protein aggregates can vary across different disorders,
but generally protein aggregation results from proteins that fold into an abnormal conforma‐
tion, leading to the formation of oligomeric intermediates [70]. These smaller aggregates, both
structured and unstructured, continue to grow and multimerize into larger aggregates or
inclusions. Larger cytoplasmic inclusions can evolve further and coalesce into an aggresome,
a pericentriolar, membrane-free cytoplasmic inclusion formed specifically at the microtubule
organizing center. It has been proposed that the aggresome is a protective structure, formed
to sequester proteins that cannot be degraded by the proteasome and packaged for degradation
by autophagy. Moreover they sequester toxic monomeric or oligomeric species diluting its
toxicity and facilitating the removal of these toxic species. However, aggregates are not
completely harmless, because they interfere with normal cellular tra฀cking and become a sink
for still-functional proteins that usually get trapped in these aggregates [71]. Their prolonged
presence in neurons is indicative of some failure in fundamental cellular processes.
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Taking this into account protein aggregation occurs and enhances the complexity that each
neurodegenerative disorders presents. Interestingly, despite the unique features of each
neurodegenerative disease, protein aggregation also shares several common characteristics.
Generally, the major component of the inclusions is often ubiquitously expressed, such as
huntingtin, alpha-synuclein and tau. Moreover the inclusions are found throughout the brain,
and they do not correlate only to the pattern of neurodegeneration that occurs in each
neurodegenerative disorder [6].
In addition, accumulation of defective, no longer functional organelles is also deleterious for
the cells [72]. Whole organelles including peroxisomes and mitochondria are degraded by
macroautophagy. If AVs containing damaged mitochondria or peroxisomes are not degraded,
damaged organelles will gradually accumulate [41, 73].Mitochondrial degradation by autoph‐
agy, known as mitophagy plays an important role in the regulation of mitochondrial function
and remodeling. Mitophagy may also be important in attenuating apoptosis or necrosis, by
clearance of damaged mitochondria. This could then prevent the release of cytochrome c, AIF
(apoptosis-inducing factor) and other apoptotic factors that lead to cell death [74]. Clearly,
autophagic removal of defective mitochondria is of crucial importance for cell survival.
Inhibition of autophagy by 3-methyladenine in growth-arrested human fibroblasts, as a model
of cell aging, results in the accumulation of lipofuscin-like material and of mitochondria, with
a low-membrane potential [75]. Enlarged and structurally deteriorated mitochondria, showing
swelling and disrupted cristae often result in the formation of amorphous material [76-77].
These mitochondria are defective in ATP production and produce increased amounts of ROS
which are harmful for cells [78]. One would think that damaged mitochondria should be
degraded, but their accumulation with age implies that they either acquire replicative
advantage over normal mitochondria, or instead they accumulate due to a decrease in
autophagic-lysosomal pathway.
Overall, autophagy is directly responsible for the maintenance of a proteome free of alterations
[79]. Importantly, autophagy by mediating the removal of damaged organelles after stress
restores organelles homeostasis being essential for the maintenance of cellular homeostasis
and to guarantee cellular survival during stress. When quality control systems fail to accom‐
plish its function is the basis for protein conformational disorders. In many late-onset neuro‐
degenerative disorders, including Parkinson’s disease (PD) and HD, there is accumulation of
intracellular protein aggregates in the brain [6]. The elimination of these intracellular protein
aggregates is often correlated with amelioration of symptoms of the disease [6]. Indeed, in mice
with deficiencies in either Atg733 or Atg534 constitutive autophagy is required for the clearance
of cytosolic aggregate-prone proteins from neurons [80].
3. Autophagy in disease
The broad array of physiological functions attributed to autophagy justifies why alterations in
this catabolic process lead to cellular malfunctioning and often cell death. Autophagy is closely
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involved in the etiology of several human diseases contributing to its pathogenesis, including
cancer, neurodegenerative diseases and metabolic disorders [81-82].
3.1. Autophagic dysfunction in neurodegenerative disorders
Alzheimer’s disease
As AD progresses, either due to AD related genes or environmental/aging factors, several
pathological changes of the lysosomal network occurs, such as deregulation of endocytosis
and increased lysosomal biogenesis culminating in a progressive failure of lysosomal clearance
mechanisms [83]. Enlargement of Rab5 and Rab7 positive endosomes is one of the earliest
specific pathology reported in AD brain tissue which reflects a pathological acceleration of
endocytosis. Interestingly, it develops in pyramidal neurons of the neocortex at a stage when
plaques and tangles are restricted only to the hippocampus. Furthermore genes involved in
endocytosis are up-regulated in AD and their corresponding proteins are abnormally recruited
to endosomes promoting fusion and enlargement of early and late endosomes, which is a
specific characteristic of AD and is not seen in normal aging brain. Acceleration of endosome
pathology is also seen in individuals who inherit the ε4 allele of APOE, the major risk factor
for late-onset AD [84-85]. Lipinski and co-workers recently reported that transcription of
factors that promote autophagy are up-regulated in the brains of AD patients, while negative
regulators of autophagy are down-regulated [86]. Indeed, cellular ultrastructural changes have
been described in AD brain biopsies revealing a high level of AVs within dystrophic neurites
[87]. AVs and lysosomes constitute more than 95% of the organelles in dystrophic neuritic
swellings in AD. This means that autophagy initiation is up-regulated or its progression is
either delayed or impaired. However the profuse and selective accumulation of AVs in
dystrophic neurites indicates a defect in the clearance of AVs by lysosomes rather than an
abnormally augment of autophagy. In the case of familial AD, for instance, presenilin 1 (a
ubiquitous transmembrane protein involved in diverse biological roles) mutations hinder
lysosome proteolysis and accelerate neuritic dystrophy which also supports a primary role for
failure of proteolytic clearance. Presenilin 1 is required for lysosome acidification which is
needed to activate cathepsins and other hydrolases that carry out digestion during autophagy.
Mutations in Presenilin 1 result in impaired targeting of the a1 subunit of V0-ATPase from the
endoplasmic reticulum to the lysosome. As V0-ATPase is required for acidification of the
autolysosome contents, mutations in Presenilin 1 are proposed to be involved in the defective
proteolysis of autophagic substrates in patients with AD [88]. Furthermore, Zhang and
colleagues reported for the first time, a role for presenilins in regulating lysosomal biogenesis
[89]. The role of impaired lysosomal degradation in the etiology of AD was underscored in a
study of a transgenic mouse model of this disease. In these mice, deletion of cystatin B (an
endogenous inhibitor of lysosomal cysteine proteases) stimulated the turnover of proteins by
the lysosome, enhanced the clearance of the autophagic substrates (including Aβ), and rescued
the deficient cognitive phenotype of the animals. Furthermore, in APP transgenic mouse
models of AD, undigested autophagic substrates including LC3-II, p62, and ubiquitinated
proteins accumulate in neuronal AVs [90]. This general failure to clear autophagy substrates
affects clearance of various proteins relevant to AD pathogenesis, including the protein Aβ
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and tau promoting cell death [91]. These results indicate that mutant APP overexpression alone
can lead to autophagic-lysosomal pathology. However the mechanism by which overexpres‐
sion of mutant APP may lead to impaired autophagy and neuritic dystrophy, is not well
understood. One possibility is that APP may affect the endosomal-lysosomal system. Strong
overexpression of human Aβ42 in Drosophila neurons induces age-related accumulation of
Aβ in AVs and neurotoxicity which is further enhanced by autophagy activation and is
partially rescued by autophagy inhibition [92]. These authors propose that the structural
integrity of post-fusion AVs may be compromised in Aβ42 affected neurons, leading to
subcellular damage and loss of neuronal integrity in the Aβ42 flies. Moreover, expression of
an APOΕε4 allele, but not the APOEε3 allele, in a mouse AD model increases levels of
intracellular Aβ in lysosomes, altering their function and causing neurodegeneration [93].
Interestingly, inhibition of Aβ aggregation rescues the autophagic deficits in the TgCRND8
mouse model of AD [94]. Autophagy sequesters and digests unneeded or damaged organelles,
some of which are APP-rich [95]. Autophagosomes are enriched in APP as well as APP
substrates and enzymes that are responsible for processing APP into Aβ. Under normal
circunstances Aβ is subsequently degraded by lysosomes [96-97]. Therefore autophagosomes
are a site of intracellular production of Aβ, thus upon their cellular accumulation amyloid
deposition occurs [98].
Failure of the autophagic system also compromises the elimination of aggregate forms of tau,
a protein that also accumulates in AD neurons [99]. In fact, for certain types of tau mutations,
pathogenic tau could contribute to the failure of macroautophagy, due to the toxic effect that
the still soluble forms of the protein exert in the membrane of lysosomes when they are
delivered to this compartment by CMA. Furthermore, particular mutant forms of tau have
been shown to abnormally interact with components of the lysosomal CMA translocation
machinery [100]. More interestingly, stimulation of autophagy is neuroprotective in a mouse
model of human tauopathy [101]. In addition to the defects in late stages of autophagy,
evidence suggests that autophagy might be disrupted at the level of autophagosome formation
in patients with AD. Compared with healthy individuals, the brains of patients with AD show
reduced expression of Beclin-1, which could lead to an impairment in the initiation of autoph‐
agy [95]. Transgenic mice that expressed a mutated form of the human APP on a Beclin-1
haploinsufficient background had disrupted autophagy, as well as, increased intracellular
Aβ accumulation and neurodegeneration, compared with mice that expressed the mutated
human APP in the context of a normal Beclin-1 background [95]. Caspase 3-mediated cleavage
of Beclin-1 occurs in the brains of patients with AD; thus, increased activity of this enzyme
might contribute to the loss of Beclin-1 function in individuals with this disease [102].
Parkinson’s disease
In PD the most common pathogenic protein, alpha-synuclein, is usually degraded by different
autophagic and non-autophagic pathways. Soluble forms of the protein are substrates of both
the UPS and of CMA [103]. However, macroautophagy is the only plausible way for the
elimination of the pathogenic variants of this protein once they aggregate [104]. When alpha-
synuclein aggregates can no longer be degraded by either the UPS or CMA, macroautophagy
becomes the only proteolytic pathway able to remove these proteinaceous deposits from the
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neuronal cytosol. As in the other disorders, post-translational modifications and pathogenic
forms of alpha-synuclein promote the formation of oligomeric species that interfere with the
normal functioning of the UPS [105], CMA [103] and even macroautophagy at the level of
autophagosome formation [106]. In fact, upregulation of wild-type alpha-synuclein leads to
significant inhibition of macroautophagy [107] and mutant forms of alpha-synuclein A30P and
A53T have been shown to be poorly degraded by CMA, because they are not translocated into
the lysosome although they bind to the lysosomal membrane with high affinity. Furthermore,
because of their high-a฀nity binding to the CMA receptor, they block the uptake and
degradation of other CMA substrates, leading to a general CMA blockage [103]. Indeed,
dopamine-modified alpha-synuclein, which is modified by non-covalent binding of oxidized
dopamine, not only is poorly degraded by CMA but also block degradation of other substrates
[108]. Subsequently, normal substrate proteins for CMA can no longer be turned over through
this pathway and also end up accumulating inside the affected cells. Interestingly, inhibition
of the UPS and CMA promote macroautophagy upregulation, [21] which maintains normal
levels of protein degradation and removes the cytosolic toxic and aggregated alpha-synuclein
[109]. AVs have also been described in melanized neurons of the substantia nigra in PD [110].
This accumulation is consistent with either an overproduction or impaired turnover of AVs.
Additionally, LC3-II levels were increased in patients with diffuse Lewy Body Disease and
PD, and LC3 co-localized with alpha-synuclein in most Lewy Bodies and Lewy neurites,
suggesting an increase in macroautophagy, as well as, an attempt to clear alpha-synuclein
pathology by up-regulating autophagic activation [111-113]. Furthermore, Alvarez-Erviti et
al. revealed that CMA activity, as well as, LAMP-2A and hsc70 levels were significantly
decreased in the substantia nigra from PD patients when compared to controls [114]. Likewise,
cathepsin D immunoreactivity was significantly reduced in substantia nigra neurons of PD
patients with an even greater decrease in alpha-synuclein inclusion-bearing cells [115].This
suggests the presence of abundant and dysfunctional autophagosomes and lysosomes in PD
and diffuse Lewy Body Disease. In several cell models, such as SK-SH5Y [116], BE-M17 [117],
PC12 cells [118] , as well as, in primary mesencephalic [117] or cortical neurons [119], 1-
methyl-4-phenylpyridinium (MPP+) has been shown to perturb the autophagy flux, as
mirrored by an evident increase in the number of LC3-positive autophagic vesicles, in
association with apoptotic or nonapoptotic cell death. More interestingly, cells harboring PD
patient’s mitochondria or in mitochondrial DNA-depleted cells show compromise quality
control autophagic response and defective clearance of the AVs [120]. The recently identified
physiological role for Parkin and Pink1, two PD-causative genes, in mitophagy, suggests that
alterations of this selective form of autophagy could also contribute to the pathogenesis of this
disease [121]. PINK1 encodes the serine–threonine kinase and is localized to the outer mito‐
chondrial membrane, and PARK2 encodes Parkin, an E3 ubiquitin ligase. Under basal
conditions, Parkin is mainly found in the cytosol where its ubiquitin ligase activity is inhibited
by an unknown mechanism. Loss of mitochondrial membrane potential drives the recruitment
of Parkin to the mitochondria. In fact, under physiologic and pathologic stress, Parkin is
selectively recruited from the cytosol to damaged mitochondria in a PINK-1-dependent
manner where ubiquinates membrane proteins such as voltage-dependent anion channel 1
and mitofusins 1 and 2, mediating the elimination of the mitochondria by mitophagy [122-124].
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Neurodegeneration in PINK-1 and Parkin-positive familial forms of PD may result from a
defect in mitophagy, leading to the accumulation of damaged mitochondria and excessive ROS
production. In fact, Parkin-deficient mice accumulate dysfunctional mitochondria and
oxidative damage [125] while Drosophila flies with mutated Parkin are particularly sensitive
to oxygen radical stress [126]. In addition, other PD causative gene, DJ-1 also plays a protective
role in autophagy. Loss of DJ-1 has been shown to result in decreased basal autophagy [127].
Moreover, Irrcher and co-workers demonstrated that DJ-1 deficiency leads to altered autoph‐
agy in murine and human cells [128]. McCoy and Cookson also showed that loss of DJ-1 leads
to mitochondrial phenotypes including reduced membrane potential, increased fragmentation
and accumulation of autophagic markers [129]. Moreover, Lrrk2 gene which is mutated in
certain dominant forms of familial PD was shown to modulate autophagy. For instance,
G2019S mutation induces autophagy via MEK/ERK pathway and inhibition of this exacerbated
autophagy reduces the sensitivity observed in G2019S mutant cells [130]. Furthermore, Lrrk2
was shown to co-localize with markers of the endosomal–lysosomal pathway in cases of
diffuse Lewy Body Disease [131]. Loss of function of Lrrk2 mutants have been shown to
decrease neuritic arbor and to cause the accumulation of autophagic vesicles and swollen
lysosomes containing tau inclusion bodies [132]. However, the precise mechanism(s) by which
LRRK2 regulates autophagy are still elusive. Interestingly, recent data suggest a mechanism
involving late steps in autophagic-lysosomal clearance in a manner dependent on NAADP
(nicotinic acid-adenine dinucleotide phosphate)-sensitive lysosomal Ca2+ channels [133]. Other
connection between autophagy and PD has been established in studies where mutant forms
of the ubiquitin carboxyl-terminal esterase L1 (UCHL-1) described in some familial forms of
PD were shown to interact abnormally with CMA components, namely hsc70, hsp90, and
LAMP-2A. The abnormally binding between UCHL-1 and these three CMA components was
proposed to interfere with CMA activity [134].
3.2. Autophagic dysfunction in lysosomal storage disorders
Lysosomes are ubiquitous organelles that have crucial roles in cellular clearance. Individually
rare, it is now known that about 1 in 7500 live-born infants in many populations will have a
lysosomal disease [135]. The LSDs are a group of over 60 diseases, clinically characterized by
a progressive phenotype involving multiple organs and tissues, including severe neurode‐
generation [136]. Indeed, LSDs involving primary defects in lysosome function commonly
exhibit prominent neurodegenerative phenotypes, including neuritic dystrophies closely
resembling the ultrastructural morphologies of dystrophic neurites in AD and, in some of these
disorders, neurofibrillary tangles as well as increased amyloidogenic processing of APP and
diffuse Aβ deposits [137]. Walter and colleagues demonstrated in LSDs an accumulation of
sphingolipids, as occurs in lysosomal lipid storage disorders and, decreases the lysosome-
dependent degradation of APP C-terminal fragments that stimulates γ-secretase activity
increasing the generation of both intracellular and secreted Aβ. Notably, primary fibroblasts
from patients with different storage diseases show strong accumulation of potentially
amyloidogenic APP C-terminal fragments [138]. LSDs are characterized by progressive
accumulation of undigested metabolites such as glycogen, ceramide, heparin sulphate and
glucocerebroside, among others, within the cell due to lysosomal dysfunction. Loss-of-
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function of lysosomal proteins causes accumulation of autophagic and endosomal substrates,
and as a result lysosomal storage. Such proteins include lysosomal enzymes, lysosomal
integral membrane proteins, and proteins involved in the post-translational modification and
trafficking of lysosomal proteins. Defects in these proteins involved in lysosome regulation or
function induce the accumulation of undigested molecules that can subsequently alter many
cellular processes. These include lysosomal pH regulation, synaptic release, endocytosis,
vesicle maturation, autophagy, exocytosis and Ca2+ homeostasis [139-140]. As a consequence,
many tissues and organ systems are affected, including brain, viscera, bone and cartilage, with
early onset central nervous system dysfunction predominating. Although individuals with
LSDs can display early symptoms, the majority are clinically normal at birth which suggests
that lysosomal dysfunction per se does not impact significantly the events of early brain
development. Furthermore children typically meet early development milestones signifying
that lysosomal storage does not affect neuronal function and maturation at early develop‐
mental stages. In patients with these disorders, dysfunction of a lysosomal enzyme (usually
one of the many lysosomal hydrolases) causes impaired degradation of the enzyme’s substrate,
which accumulates within lysosomes [136]. An abundance of AVs is a common feature of cells
from patients with LSDs. Lysosomal storage impairs autophagic delivery of bulk cytosolic
contents to lysosomes. This can be attributed to a defect in autophagosome–lysosome fusion
as a result of dysfunction of the lysosomal compartment. This, in turn, leads to a progressive
accumulation of poly-ubiquitinated protein aggregates and of dysfunctional mitochondria,
suggesting that neurodegeneration in LSDs may share mechanisms with some neurodegener‐
ative disorders in which the accumulation of protein aggregates is a prominent feature [141].
This defect in autophagosome-lysosome fusion can result from an impairment of vesicular
trafficking due to a microtubule-based transport deficiency. The motor protein dynein
mediates the movement of mature autophagosomes towards lysosomes. Indeed, mutations
affecting dynein impair the autophagic degradation of aggregate‑prone proteins [54]. Another
possible mechanism involves changes in the lipid composition of lysosomal membranes. In
fact, lipids have been demonstrated to accumulate in a wide range of LSDs [142]. These lipids
are the principal constituents of lipid‑rafts. Since lipid‑rafts play a critical role in membrane
physiology influencing their plasticity, it is possible that the abnormal accumulation of lipids
in LSDs leads to an increase in lipid‑rafts that affects the dynamics of lysosomal membranes
and specifically their ability to fuse with autophagosomes. Indeed, in conditions that are
similar to what is found in Niemann Pick type C diseases-1 and-2, cholesterol accumulation
in late endosomes perturb the intra-endosomal trafficking affecting most likely autophago‐
some maturation [143].
Impaired autophagy has been reported in several models of LSDs, including Pompe disease,
Niemann-Pick disease, the neuronal ceroid lipofuscinoses, multiple sulphatase deficiency, and
GM1-gangliosidosis. Additionally, lysosomal function is intimately linked to exocytosis
(removal of cellular cargo by fusion of vesicle with the plasma membrane), and multiple LSDs,
such as mucolipidosis type I, Niemann-Pick disease and sialidosis have been shown to have
impaired exocytosis [144].
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The first LSD in which an involvement of autophagy was reported was Danon disease (also
called “glycogen storage disease due to LAMP2 deficiency” or “lysosomal glycogen storage
disease with normal acid maltase activity”) [145]. It was reported an accumulation of AVs in
several tissues, particularly the muscle, from a mouse model of the disease [146]. The disease,
extremely rare, is inherited as an X-linked trait and the disease phenotype is characterized by
severe cardiomyopathy and variable skeletal muscle weakness often associated with mental
retardation.
Another LSD is Multiple sulfatase deficiency which is attributed to deficiencies in the activity
of sulfatase enzymes. The sulfatases are a family of enzymes that catalyze the hydrolysis of
sulfate ester bonds in a wide variety of substrates, ranging from complex molecules, such as
glycosaminoglycans, to sulfolipids and steroid sulfates. These enzymes can be divided, at least
in mammals, into two main groups based on their subcellular localization: those found in
lysosomes (acting at an acidic pH) and those found in the endoplasmic reticulum, the Golgi
apparatus and at the cell surface (acting at a neutral pH) [147]. Sulfatases are activated upon
a post-translational modification by sulfatase modifying factor 1. The gene encoding sulfatase
modifying factor 1 in humans is mutated in this rare autosomal recessive disorder, in which
the activity of all sulfatases is profoundly impaired [148]. As for other types of LSDs, the
pathogenic mechanisms that lead from enzyme deficiency to cell death in Multiple sulfatase
deficiency is not completely understood. An impairment of autophagy is postulated to play a
major role in disease pathogenesis. In mouse models of multiple sulfatase deficiency, it was
observed an accumulation of autophagosomes resulting from defective autophagosome-
lysosome fusion which was demonstrated by the inefficient degradation of exogenous
aggregate-prone proteins (expanded huntingtin and mutated alpha-synuclein) and defective
organelles [59]. Moreover in chondrocytes from multiple sulfatase deficiency mice show a
severe lysosomal storage defect and a defective autophagosome digestion leading to a defect
in energy metabolism and to cell death [149]. Interestingly, the mechanisms underlying the
impairment of the fusion between lysosomes and autophagosomes in multiple sulfatase
deficiency seems to involve abnormalities of membrane lipid composition and SNARE protein
distribution [150]. Overall, it seems that a global lysosomal dysfunction leads to the impaired
autophagy observed in the pathogenesis of multiple sulfatase deficiency.
Niemann-Pick type C disease is caused by mutations in the NPC1 or NPC2 genes, [151] whose
protein products are thought to act cooperatively in the efflux of cholesterol from late endo‐
somes and lysosomes [152]. In the Niemann–Pick type C disease defects in lysosomal traffick‐
ing and biogenesis occur. Moreover, a marked accumulation of autophagosomes occurs in the
brains of Niemann–Pick disease type C mice and in skin fibroblasts from Niemann–Pick
disease type C patients [153-155]. Using human embryonic stem cell-derived neurons engi‐
neered to mimic the cholesterol lysosomal storage disease Niemann Pick type C, we have
shown that excessive activation and impaired progression of the autophagic pathway lead to
abnormal mitochondrial clearance [156]. NPC1 deficiency leads to both an induction of
autophagy and an impairment of autophagic flux. The impairment in degradation of auto‐
phagic substrates may contribute to several aspects of NPC neuropathology, including the
accumulation of ubiquitinated proteins and the generation of ROS.
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Gaucher’s disease is an autosomal recessive condition, due to deficient activity of lysosomal
β-glucosylceramidase. The pathologically enlarged and often multinucleate ‘storage’ cell is a
striking feature of Gaucher’s disease. Similarly to Niemann-Pick type C disease, also models
of Gaucher disease show both an induction of autophagy and an accumulation of autophago‐
somes and autophagic substrates [157-158].
In LSDs the primary alteration of the lysosomal compartment can indirectly affect CMA
activity.  However,  there  are  two  LSDs  for  which  alterations  in  CMA are  not  merely  a
consequence  of  the  lysosomal  alteration,  but  rather  are  due  to  the  possible  functional
association of the mutant protein with CMA, such as galactosialydosis and mucolipidosis
type  IV.  The  first  one  is  caused by  a  mutation or  loss  of  cathepsin  A gene  which is  a
protease involved in CMA regulation and contributes to lysosomal activity and stability.
Moreover  is  also  involved  in  the  degradation  of  LAMP-2A  [159].  Loss  of  cathepsin  A
enzymatic activity leads to slower LAMP-2A degradation resulting to an increase in CMA
activity which contributes to an extreme weight loss that characterizes these patients.  In
the second LSD the mutated protein, the transient receptor potential mucolipin-1 (TRPML1)
which  is  a  endolysosomal  cation  channel,  interacts  with  HSPA8  (HSC70)  and  DNAJB1
(HSP40),  two components  of  the CMA molecular  machinery leading to decreased CMA
activity in response to serum removal [160]. Moreover it has been suggested that TRPML1
mediates Ca2+ efflux from late endosomes and lysosomes indicating that TRPML1 is a key
regulator of membrane trafficking along the endosomal pathway [161]. In fact, in TRPML1-
deficient  cells  the delivery of  cargo from the cell  surface to the lysosome and fusion of
lysosomes with the plasma membrane is impaired [162-163].
In spite of all the above mentioned differences among diseases in most cases there is an
impairment of autophagic flux, causing a secondary accumulation of autophagy substrates
and on the other hand an increase in factors involved in autophagosome formation, such as
Beclin1, as an attempt to compensate for the impaired autophagic flux. Accordingly, LSDs can
be seen primarily as “autophagy disorders.” [164].
3.3. Autophagic dysfunction in diabetes
In response to a variety of metabolic stressors such as nutrient starvation, growth factor
withdrawal,  high lipid content challenges or hypoxia macroautophagy and CMA can be
induced  [165].  Moreover  autophagy  is  also  capable  of  mobilizing  energetically  efficient
molecules,  such as lipids,  glycogen and nucleic  acids which can be used by TCA cycle,
gluconeogenesis and glycolysis to produce ATP [165-166]. This capability of autophagy to
maintain ATP production and support macromolecular synthesis makes it a pro-survival
pathway of particular importance in organs with high energetic requirements, such as the
heart  or  skeletal  muscles.  Therefore,  alterations  of  this  specific  autophagic  function  can
constitute the basis of some common metabolic disorders such as diabetes. Type II diabe‐
tes  is  caused,  in  most  cases,  by  the  inability  of  the  body  to  buffer  the  free  fatty  acid
concentration.  This  increases  the redox pressure on the mitochondrial  respiratory chain,
increases ROS production, reduces mitochondrial function, and increases apoptosis of beta-
cells  [167].  Moreover  it  is  characterized  by  insulin  resistance  and  failure  of  beta-cells
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producing insulin.  The most potent fatty acid causing insulin resistance is palmitate.  As
palmitate  is  the  precursor  of  ceramide  and  sphingolipid  biosynthesis,  the  sphingolipid
pathway  has  been  implicated  in  the  etiology  of  insulin  resistance  [168].  Interestingly,
ceramide has been shown to activate autophagy by upregulating beclin1 [169]. Moreover a
decrease  in  intracellular  aminoacid  concentrations  and  a  decrease  in  mTOR-dependent
signaling may also contribute to the activation of autophagy by ceramide [170]. If in fact
autophagy turns out to be up-regulated in type II diabetes, we could speculate that the onset
of insulin resistance in elderly people could be an adaptive mechanism aiming to increase
autophagy  and  helping  to  improve  the  ability  to  remove  damaged  organelles  [171].
Autophagy is inhibited by the insulin -mTOR signaling pathway and can be activated either
upon aminoacid depletion or by rapamycin administration. Insulin inhibits autophagy in
two  ways:  first  by  activating  mTOR  in  synergy  with  aminoacids,  which  results  in  the
phosphorylation and inhibition of the protein kinase Atg1 (ULK1 in mammals); and second
by protein  kinase  B-mediated phosphorylation and inhibition of  the  transcription factor
FoxO3, which is responsible for the expression of ATG genes [172]. Because insulin inhibits
autophagy in insulin-sensitive cells,  such as beta-cells,  autophagy might be increased. In
addition, as a result of free fatty acid induced oxidative stress insulin resistance develops
in response to over-feeding, which is one of the major causes of insulin resistance. Interest‐
ingly, ROS are known to be required to trigger autophagy, probably because they oxidize
a critical cysteine residue in Atg4 [173]. A report from 2007 showed that oxidative stress
induced  by  diabetes  leads  to  ubiquitination  and  storage  of  proteins  into  cytoplasmatic
aggregates  that  do  not  co-localize  with  insulin.  Because  accumulation  of  ubiquitinated
protein  may  damage  cells,  such  data  suggests  that  autophagy  may  contribute  to  the
regulation of beta-cell  survival and death acting as a defense to cellular damage during
diabetes [174]. To prove that a relationship between autophagy and beta-cell death indeed
exists experiments were performed in a mouse model whose beta-cells were deficient in
autophagic activity. In beta-cell specific Atg7 knockout mice it was reported by two different
studies islet degeneration, decreased glucose tolerance, insulin secretion and accumulation
of large ubiquitin-containing protein aggregates indicating that autophagy was impaired.
This happened even with overexpression of LC3-binding protein p62, which is required for
polyubiquitinated protein aggregates to be delivered to the autolysosome [175-176]. In beta-
cells from diabetic animals the levels of autophagosomes was significantly increased in both
diabetic db/db mice and in non-diabetic control mice fed with a high-fat diet. This can occur
either as a result of impaired autophagosome/lysosome fusion, or impaired function of the
lysosomal proton pump. Interestingly when Atg7(-/-)  mice were fed with a high-fat diet
their glucose tolerance decreased indicating once again the important role of autophagy in
maintaining proper beta-cell function under stressful conditions. Ebato and colleagues also
showed that free fatty acids which can cause peripheral insulin resistance associated with
diabetes induced autophagy in beta-cells [176]. These findings suggest that basal autopha‐
gy is important for maintenance of normal islet architecture and function and protects beta-
cells against cell damage [177]. Interestingly in autophagy-deficient beta-cells ubiquitinated
proteins accumulated inside cells. Moreover also p62, a specific autophagy substrate also
accumulated  in  autophagy-deficient  beta-cells  [178].  Furthermore,  exposure  of  human
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neuroblastoma  SH-SY5Y  cells  to  sera  from  type  2  diabetic  patients  with  neuropathy  is
associated with increased levels of autophagosomes [179]. Jung and co-workers showed that
the presence of  defective beta-cell  mitochondria  and endoplasmic reticulum presumably
contributed to the reduced ability to produce insulin, indicating that decreased function and
mass of beta-cells can result from mitochondrial dysfunction and endoplasmic reticulum
stress, since both organelles are autophagic substrates [175].Moreover, deregulated autoph‐
agy may be involved in insulin resistance.  In fact,  mitochondrial  impairment and defec‐
tive endoplasmic stress response have been implicated in insulin resistance [180-182].  In
pancreatic beta-cells, the endoplasmic reticulum is the crucial site for insulin biosynthesis.
Consequently, perturbations to endoplasmic reticulum function of the beta-cell, such as those
caused by high levels of free fatty acid and insulin resistance, can lead to an imbalance in
protein  homeostasis  and ER stress,  which  has  been recognized as  an  important  mecha‐
nism for  type 2  diabetes.  Macroautophagy is  activated as  a  novel  signaling pathway in
response to ER stress [183]. In the brain of young patients with poorly controlled type I
diabetes  mellitus  and  fatal  diabetic  ketoacidosis  was  demonstrated  increased  levels  of
macroautophagy-associated proteins as well as increased levels of the ER-associated GRP78.
Therefore  probably  chronic  metabolic  instability  and  oxidative  stress  may  cause  altera‐
tions in the autophagy-lysosomal pathway [184].
Interestingly, insulin resistance, one of the major components of type II diabetes mellitus is a
known risk factor for AD. Son and co-workers observed that insulin resistance promotes Aβ
generation in the brain via altered insulin signal transduction, increased BACE1/β-secretase
and γ-secretase activities, and accumulation of autophagosomes. These authors proposed that
the insulin resistance that underlies the pathogenesis of type II diabetes mellitus might alter
APP processing through autophagy activation, which might be involved in the pathogenesis
of AD [185].
4. Targeting autophagy
The evidence indicating that induction of autophagy is cytoprotective in neurodegenerative
disease models raises the possibility that this intracellular catabolic pathway may be exploited
to clear toxic disease proteins and provide therapeutic benefit for patients. Consequently, novel
approaches to manipulating autophagy in human patients are desirable.
Using a yeast screen, one recent study identified several small molecules capable of augment‐
ing autophagy in mammalian cells and further demonstrated therapeutic benefit of these
compounds in a Drosophila model of neurodegeneration [186].
Knockdown of autophagy blocks the protective effects of delayed aging, suggesting that
neuroprotection associated with manipulation of aging pathways is autophagy dependent
[97]. These results are consistent with the notion that protein aggregation neuronal dysfunction
might occur coincidentally with age-related decline in cellular mechanisms to deal with
misfolded protein species. Thus, the age-related onset of pathology in neurodegenerative
conditions might be correlated with a decline in autophagic capacity beyond a critical thresh‐
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old. However, additional studies will be required to define the precise relationship of aging,
autophagy and neurodegeneration. In the case of some diseases autophagy is initially induced
as a neuroprotective response in stressed or injured neurons, but is subsequently overwhelmed
or impaired by disease-related factors. This could partly account for evidence that autophagy
seems to be both induced and impaired in several major neurodegenerative diseases. Over‐
expression of HDAC6, a cytoplasmic deacetylase containing a ubiquitin-binding domain, was
found to suppress neurodegeneration in a model of polyglutamine disease and to compensate
for defects in the UPS by facilitating autophagic protein degradation [187]. These results
suggest that HDAC6 functions at the intersection of the UPS and autophagy and identify
HDAC6 as a promising target for pharmacological manipulation in neurodegeneration.
Pharmacological activation of autophagy can be achieved with rapamycin, a lipophilic
macrolide antibiotic. Chronic low-level stimulation of autophagy through peripheral admin‐
istration of rapamycin or other agents [188], or enhancing lysosomal proteolysis selectively
[90, 189], can markedly diminish Aβ levels and amyloid load in APP transgenic mice, under‐
scoring the importance of lysosomal clearance of Aβ. In both APP and triple transgenic mouse
models of AD for instance peripheral administration of rapamycin significantly reduces Aβ
deposition and tau pathology [188, 190-191]. Furthermore, by deleting an endogenous inhibitor
of lysosomal cysteine proteases (cystatin B) in the TgCRND8 APP mouse model lysosomal
pathology is rescued and abnormal autolysosomal accumulation of autophagy substrates
including Aβ is decreased and learning and memory deficits also ameliorate [90]. In addition,
inhibition of mTOR by rapamycin improves cognitive deficits and rescues Aβ pathology and
intraneuronal neurofibrillary tangles by increasing autophagy [192]. In a cell model of HD
treatment with rapamycin reduced cellular toxicity by reducing bolth levels of soluble mutant
huntingtin and the formation of intracellular aggregates [193]. Likewise this was also repli‐
cated in vivo in both Drosophila and mouse models of HD [194]. Furthermore, treatment of
animals with rapamycin ameliorated neuronal toxicity in models of both Frontotemporal
Dementia, spinocerebellar ataxia type 3, and PD [195-199]. However rapamycin shows
autophagy-independent functions, such as regulation of ribosome biogenesis and protein
translation. Taking into account that rapamycin may not be a good choice for the treatment in
humans, other compounds that are independent of mTOR pathway are being studied.
Moreover, long-term massive degradation of intracellular components as a result of the
upregulation of macroautophagy can have possible negative consequences. Current efforts are
now focused on the identification of other methods that can activate macroautophagy.
The mood stabilizer lithium used in bipolar disorder induces autophagy independently of
mTOR through the inhibition of inositol monophosphatase therefore depleting the intracel‐
lular signaling molecule IP3 [200-201]. Lithium enhances clearance of aggregate-prone
proteins, such as mutant forms of huntingtin and alpha-synuclein [202]. Likewise, sodium
valproate and carbamazepine are other mood stabilizing drugs that can also reduce the
accumulation and toxic effects of aggregation-prone mutant proteins in cell models and protect
against neurodegeneration in vivo. Enhanced clearance of mutant alpha-synuclein and
neuroprotective effects through lithium were demonstrated in cell-culture models and mice,
underscoring the potential of lithium and related molecules for further evaluation [203-204].
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An interesting study has shown that lithium (when given in addition to riluzole), significantly
delayed the onset of disability and death in human Amyotrophic lateral sclerosis patients,
compared to those administered riluzole alone [205]. In addition, prolonged lithium treatment
alleviates memory deficits and reduces Aβ production in AD mouse models [206]. On 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism mice valproate
combined with lithium carbonate rescued dopaminergic neurons and ameliorated the loss of
DOPAC, likely via activation of autophagic/lysosomal pathways [207].
The disaccharide trehalose is a stable disaccharide with unique physicochemical properties.
This disaccharide directly acts as a chemical chaperone that can stabilize misfolded proteins
but it also facilitates the clearance of aggregate-prone proteins. Trehalose was shown to
augment autophagy and enhance the clearance of mutant forms of huntingtin and alpha-
synuclein from neuronal cells in culture [208]. In APP(swe) mutant mice co-treatment with
trehalose increases the expression of autophagic markers as well as the expression of chaper‐
ones and reduces the levels of Aβ peptide aggregates, tau plaques and levels of phospho-tau
[209]. Moreover in PC12 cells overexpressing wild-type or A53T mutant alpha-synuclein
trehalose promoted the clearance of A53T alpha-synuclein but not wild-type alpha-synuclein
in PC12 cells, and increased LC3 and Lysotracker RED positive AVs by using lysotracker and
LC3 staining [210].
These findings have opened the possibility of using autophagy modulators as therapeutic
approaches for these types of pathology. Therefore the search for chemical autophagy
modulators more selective and potency is ongoing. Nevertheless, there are certain limitations
in the use of up-regulation of macroautophagy for anti-neurodegenerative purposes. One of
the limitations is that they all act on early steps of macroautophagy enhancing autophagosome
formation, but will not have a beneficial effect in those pathological conditions in which the
autophagic defect is in steps past autophagosome formation. Moreover, it has been reported
that not all protein aggregates are recognized by the macroautophagic machinery. Further
studies are needed to address whether expression of other cellular components or specific post-
translational modifications in the aggregated proteins could enhance their recognition by the
autophagic systems. For example, pharmacological induction or inhibition of macroautophagy
alters the rate of turnover of polyglutamine-expanded proteins, polyalanine-expanded
proteins, as well as, wild-type and mutant forms of alpha-synuclein [193, 211].
A patent by Harvard and Cambridge Universities disclosed novel small molecule enhanc‐
ers of autophagy, named SMERs (small molecule enhancers of rapamycin) [President and
Fellows  of  Harvard  College,  Dana  Farber  Cancer  Institute,  Cambridge  Enterprise  Ltd.
Regulating autophagy. WO2008122038 (2008)]. In mammalian cells, the three most active
compounds: SMER10, SMER18 and SMER28, augmented autophagosome formation in an
mTORC1-independent fashion and without affecting the levels of Beclin-1, Atg5, Atg7 and
Atg12, or enhancing the conjugation of Atg12 to Atg5. Importantly, SMERs enhanced the
clearance  of  aggregation-prone  mutant  forms  of  alpha-synuclein  and  huntingtin  in
mammalian cells  [186].  In addition,  in cell  lines and primary neuronal cultures SMER28
reduced  the  levels  of  Aβ  and  APP  C-terminal  fragments  [188].  In  addition,  drugs  that
involve the serine/threonine-protein kinase mammalian target  of  rapamycin (mTOR) are
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being  currently  examined  for  the  treatment  of  metabolic  disorders,  such  as  diabetes
mellitus. However future investigations are necessary [212]. Drugs that take advantage of
the potential protective effect of autophagy in ER stress, such as glucagon like peptide-1,
will be a promising avenue of investigation [183, 213].
5. Concluding remarks
The progression of research in the field of autophagy has taken the understanding of autoph‐
agy from a means of survival during starvation to a possible means of treating pharmacolog‐
ically diseases where autophagy holds an important role. Progress in understanding
autophagy has emphasized the importance of autophagy in cellular homeostasis and quality
control; prevention of neurodegeneration in several animal models, and the significance of its
deficiency in the development and pathogenesis of several disorders. This may provide further
insights into the role that autophagy has in disease and how it may be possibly use it as a
therapeutic strategy.
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